Aktienanalyse zu Tango Therapeutics Inc (TNGX)TNGXTango Therapeutics Inc

Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. The Company is focused on clinical development of two methylthioadenosine phosphorylase (MTAP)-deleted selective PRMT5 inhibitors: vopimetostat (TNG462) for non-CNS cancers, both as a monotherapy and in combination with RAS inhibitors, and TNG456, brain-penetrant protein arginine methyltransferase 5 (PRMT5) inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of the Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Tango Therapeutics Inc (TNGX) appears to be a good buy right now. The current price is $23.81, and analysts have set a price target as high as $60, suggesting a potential upside of over 150%. The stock has shown impressive performance with a year-to-date change of +166.63% and a 1-year change of +181.11%. The RSI is at 57.019, indicating a healthy momentum without being overbought. However, the main risk is the high short interest at 29.53%, which could lead to volatility in the stock price.